書誌事項
- タイトル別名
-
- Current Research into Head and Neck Cancer Molecular Targeted Therapy and Human Papilloma Virus Infection in Head and Neck Squamous Cell Carcinoma
- 頭頸部癌研究に関する最近の流れ : 分子標的治療とHPV感染について
- アタマ ケイブガン ケンキュウ ニ カンスル サイキン ノ ナガレ : ブンシ ヒョウテキ チリョウ ト HPV カンセン ニ ツイテ
この論文をさがす
抄録
Despite recent advances in surgical technology and chemoradiation regimens, no significant improvement has been seen in the survival rate of head and neck squamous cell carcinoma (HNSCC) in more than 3 decades. Examples of new and remarkable clinical strategies such as epidermal growth factor receptor(EGFR) targeted therapy and the status of human papilloma virus (HPV) infection in oropharyngeal carcinoma have attracted attention over the years.<br> Molecular-targeted therapy has been approved in Europe and the United States as standard treatment for HNSCC and has shown significant effect with conventional chemotherapy and radiotherapy. However, the therapeutic effect is heterogeneous as is the case with other cancers, and problems have also been highlighted such as acquired resistance associated with long-term treatment.<br> Recent studies have shown that a subset of HNSCC, especially in the oropharynx, is caused by HPV infection and that the clinical outcome of patients can be clearly distinguished based on their HPV status. Patients with HPV(+) tumors have a more favorable prognosis compared to HPV(−) patients. The use of the HPV status as a marker for personalized treatment has been anticipated. In this paper, we show our recent data on EGFR-targeted therapy and the clinical outcome of patients depending on their HPV status, and we discuss the future of translational research in HNSCC.<br>
収録刊行物
-
- 耳鼻咽喉科臨床
-
耳鼻咽喉科臨床 105 (3), 183-191, 2012
耳鼻咽喉科臨床学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001204272797440
-
- NII論文ID
- 10030176465
-
- NII書誌ID
- AN00107089
-
- ISSN
- 18844545
- 00326313
-
- NDL書誌ID
- 023577340
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可